menu
    • menu
    [{"orgOrder":0,"company":"Therabel Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"BELGIUM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Molsidomine","moa":"antianginals (sydnone derivatives)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Therabel Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Therabel Pharma \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Therabel Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Therabel Pharma","sponsor":"ECSOR","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"BELGIUM","productType":"Probiotic","year":"2017","type":"Inapplicable","leadProduct":"Prolardii","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Therabel Pharma","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Therabel Pharma \/ ECSOR","highestDevelopmentStatusID":"1","companyTruncated":"Therabel Pharma \/ ECSOR"}]

    Find Clinical Drug Pipeline Developments & Deals by Therabel Pharma

    Menu

    Therabel Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Therabel Pharma

                            Belgium arrow
                            BOS Manchester
                            Not Confirmed

                            Therabel Pharma

                            Belgium arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Prolardii

                            Therapeutic Area : Gastroenterology

                            Study Phase : Undisclosed

                            Sponsor : ECSOR

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Prevention of Antibiotic-Associated Diarrhoea With Prolardii

                            Details : Prolardii is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Diarrhea.

                            Product Name : Undisclosed

                            Product Type : Probiotic

                            Upfront Cash : Inapplicable

                            August 22, 2017

                            Lead Product(s) : Prolardii

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Undisclosed

                            Sponsor : ECSOR

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Therabel Pharma

                            Belgium arrow
                            BOS Manchester
                            Not Confirmed

                            Therabel Pharma

                            Belgium arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Molsidomine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Molsidomine on the Endothelial (Internal Layer of Blood Vessels) Dysfunction in Patients With Angina...

                            Details : Molsidomine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Angina, Stable.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 01, 2011

                            Lead Product(s) : Molsidomine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth